Evidence map›Paper›PMID 41189495›Full record

ArticleThe Journal of infectious diseases2026

Daptomycin-Loaded Nanocarriers Facilitate Synergistic Killing of Methicillin-Resistant Staphylococcus aureus via Lipid-Mediated Interactions and Targeting.

Jhih-Hang Jiang, Chia Xin Lim, Xiangfeng Lai, Xenia Kostoulias, Faye C Morris, Anton P Le Brun, Chun-Ming Wu, Nageshwar R Yepuri, Hsin-Hui Shen, Anton Y Peleg

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jhih-Hang JiangInfection Program, Monash Biomedicine Discovery Institute and Department of Microbiology, Monash University, Clayton, Victoria, Australia.ORCID 0000-0002-1543-1634
Chia Xin LimBiomedicine Discovery Institute and Department of Biochemistry, Monash University, Clayton, Victoria, Australia.
Xiangfeng LaiDepartment of Materials Science and Engineering, Faculty of Engineering, Monash University, Clayton, Victoria, Australia.ORCID 0000-0002-2558-4415
Xenia KostouliasInfection Program, Monash Biomedicine Discovery Institute and Department of Microbiology, Monash University, Clayton, Victoria, Australia.ORCID 0000-0002-8611-2198
Faye C MorrisInfection Program, Monash Biomedicine Discovery Institute and Department of Microbiology, Monash University, Clayton, Victoria, Australia.ORCID 0000-0002-9021-0452
Anton P Le BrunAustralian Centre for Neutron Scattering, Australian Nuclear Science and Technology Organisation, Kirrawee DC, New South Wales, Australia.ORCID 0000-0003-2431-6985
Chun-Ming WuNational Synchrotron Radiation Research Center, Hsinchu Science Park, Hsinchu, Taiwan.ORCID 0000-0002-2476-2785
Nageshwar R YepuriNational Deuteration Facility, Australian Nuclear Science and Technology Organisation, Kirrawee DC, New South Wales, Australia.ORCID 0000-0002-4665-1306
Hsin-Hui ShenBiomedicine Discovery Institute and Department of Biochemistry, Monash University, Clayton, Victoria, Australia.ORCID 0000-0002-8541-4370
Anton Y PelegInfection Program, Monash Biomedicine Discovery Institute and Department of Microbiology, Monash University, Clayton, Victoria, Australia.ORCID 0000-0002-2296-2126

Funding

Australian National Health and Medical Research CouncilNHMRC APP1144303NHMRC APP2002921
6 · The paper itself

Abstract

Preservation and augmentation of existing antimicrobials is crucial in combating antimicrobial resistance. Gram-positive bacteria, exemplified by Staphylococcus aureus, are among the most common human bacterial pathogens, with methicillin-resistant S. aureus (MRSA) now established globally. Daptomycin is a last-line anti-staphylococcal antimicrobial that uniquely targets the bacterial membrane with bactericidal effects. Here, we developed lipid-based nanoparticles, namely cubosomes, to encapsulate daptomycin for targeted delivery via lipid-mediated interactions. Daptomycin-loaded cubosomes synergistically killed 14 clinical MRSA isolates in vitro compared with daptomycin or cubosomes alone. This synergy between daptomycin and cubosome was mediated by cubosomes docking on the S. aureus cell surface, releasing daptomycin for membrane extraction and penetration, followed by lipid cubosome infusion into S. aureus membranes. Using a murine septicemia model, daptomycin-loaded cubosomes significantly reduced the organ bacterial burden of MRSA. Together, these data showed that multifunctional lipid nanocarriers can potentiate the bactericidal activity of daptomycin using a membrane-targeted trojan-horse-like mechanism.

Indexed as

Anti-Bacterial AgentsDaptomycinDrug CarriersMethicillin-Resistant Staphylococcus aureusNanoparticlesAnimalsDisease Models, AnimalDrug SynergismFemaleHumansLipidsMiceMicrobial Sensitivity TestsSepsisStaphylococcal InfectionsAnti-Bacterial AgentsDaptomycinDrug CarriersLipidsantimicrobial resistancecell membranecubosomesdaptomycinMRSA

Identifiers

PMID41189495
PMCPMC12811857

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.